Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

40 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prospective study to optimize care and improve knowledge on ovarian function and/or fertility preservation in young breast cancer patients: Results of the pilot phase of the PREgnancy and FERtility (PREFER) study.
Lambertini M, Fontana V, Massarotti C, Poggio F, Dellepiane C, Iacono G, Abate A, Miglietta L, Ferreccio C, Pescio MC, Conte B, Blondeaux E, Bighin C, D'Alonzo A, Vaglica M, Zanardi E, Boccardo F, Ballestrero A, Anserini P, Del Mastro L. Lambertini M, et al. Among authors: blondeaux e. Breast. 2018 Oct;41:51-56. doi: 10.1016/j.breast.2018.06.012. Epub 2018 Jun 22. Breast. 2018. PMID: 30007268
Potential Mechanisms of Ovarian Protection with Gonadotropin-Releasing Hormone Agonist in Breast Cancer Patients: A Review.
Poggio F, Lambertini M, Bighin C, Conte B, Blondeaux E, D'Alonzo A, Dellepiane C, Buzzatti G, Molinelli C, Boccardo F, Del Mastro L. Poggio F, et al. Among authors: blondeaux e. Clin Med Insights Reprod Health. 2019 Jul 31;13:1179558119864584. doi: 10.1177/1179558119864584. eCollection 2019. Clin Med Insights Reprod Health. 2019. PMID: 31391786 Free PMC article. Review.
T-DM1 Efficacy in Patients With HER2-positive Metastatic Breast Cancer Progressing After a Taxane Plus Pertuzumab and Trastuzumab: An Italian Multicenter Observational Study.
Conte B, Fabi A, Poggio F, Blondeaux E, Dellepiane C, D'Alonzo A, Buono G, Arpino G, Magri V, Naso G, Presti D, Mura S, Fontana A, Cognetti F, Molinelli C, Pastorino S, Bighin C, Miglietta L, Boccardo F, Lambertini M, Del Mastro L; Gruppo Italiano Mammella (GIM) study group. Conte B, et al. Among authors: blondeaux e. Clin Breast Cancer. 2020 Apr;20(2):e181-e187. doi: 10.1016/j.clbc.2019.09.001. Epub 2019 Nov 14. Clin Breast Cancer. 2020. PMID: 31735691
Dose-dense adjuvant chemotherapy in early breast cancer patients: 15-year results of the Phase 3 Mammella InterGruppo (MIG)-1 study.
Blondeaux E, Lambertini M, Michelotti A, Conte B, Benasso M, Dellepiane C, Bighin C, Pastorino S, Levaggi A, Alonzo A, Poggio F, Buzzatti G, Molinelli C, Fregatti P, Bertoglio S, Boccardo F, Del Mastro L. Blondeaux E, et al. Br J Cancer. 2020 May;122(11):1611-1617. doi: 10.1038/s41416-020-0816-8. Epub 2020 Mar 31. Br J Cancer. 2020. PMID: 32231293 Free PMC article. Clinical Trial.
Effect of dose-dense adjuvant chemotherapy in hormone receptor positive/HER2-negative early breast cancer patients according to immunohistochemically defined luminal subtype: an exploratory analysis of the GIM2 trial.
Conte B, Bruzzone M, Lambertini M, Poggio F, Bighin C, Blondeaux E, De Laurentiis M, Valle E, Cognetti F, Nisticò C, De Placido S, Garrone O, Gamucci T, Montemurro F, Puglisi F, Cardinali B, Fregatti P, Miglietta L, Boccardo F, Ceppi M, Del Mastro L; GIM2 Investigators. Conte B, et al. Among authors: blondeaux e. Eur J Cancer. 2020 Sep;136:43-51. doi: 10.1016/j.ejca.2020.05.007. Epub 2020 Jul 4. Eur J Cancer. 2020. PMID: 32634760 Clinical Trial.
Long-Term Outcomes With Pharmacological Ovarian Suppression During Chemotherapy in Premenopausal Early Breast Cancer Patients.
Lambertini M, Boni L, Michelotti A, Magnolfi E, Cogoni AA, Mosconi AM, Giordano M, Garrone O, Arpino G, Poggio F, Cinacchi P, Bighin C, Fregatti P, Pronzato P, Blondeaux E, Del Mastro L; GIM study group. Lambertini M, et al. Among authors: blondeaux e. J Natl Cancer Inst. 2022 Mar 8;114(3):400-408. doi: 10.1093/jnci/djab213. J Natl Cancer Inst. 2022. PMID: 34850043 Free PMC article. Clinical Trial.
Prognostic value of HER2-low status in breast cancer: a systematic review and meta-analysis.
Molinelli C, Jacobs F, Agostinetto E, Nader-Marta G, Ceppi M, Bruzzone M, Blondeaux E, Schettini F, Prat A, Viale G, Del Mastro L, Lambertini M, de Azambuja E. Molinelli C, et al. Among authors: blondeaux e. ESMO Open. 2023 Aug;8(4):101592. doi: 10.1016/j.esmoop.2023.101592. Epub 2023 Jul 4. ESMO Open. 2023. PMID: 37413762 Free PMC article.
40 results